About: Double-Blind Randomized Multicenter Study Comparing the efficacy and safety of 10-day to 5-day terlipressin treatment of bleeding esophageal varices     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • Abstract: Background/Aims: The aim of the study was to compare the efficacy and safety of 5-day terlipressin treatment of bleeding esophageal varices to 10-day treatment period. Methodology: Of 25 patients with variceal bleeding, 15 were randomized to receive terlipressin for day 1-5 and placebo for day 6-10 (Group A), and 10 to receive terlipressin for day 1-10 (Group B). Results: The bleeding was stopped in 24 patients (96%). Rebleeding till day 42 was observed in 9 (36%) patients (5 in group A, 4 in group B, ns). 2 patients died in group B (due to rebleeding till day 5) and one in group A (rebleeding between day 510). Transfusion needs were lower in group B (2.7 +/- 2.6TU compared to 4.13 +/- 5.8 TU in group A, ns). Serious AE leading to treatment discontinuation were observed in 1 patient in group A (peripheral ischemia) and none in B, non-significant AE in 3 patients in group A (hypertension), and in 3 in group B (hypertension, hyponatremia, epiparoxysm). Conclusions: Prolonged treatment with terlipressin did not prove significant decrease of mortality or bleeding recurrence; lower rebleeding rate after day 5 and tendency towards lower transfusion requirements were observed. Prolonged treatment had no influence on AE rate.
  • Abstract: Background/Aims: The aim of the study was to compare the efficacy and safety of 5-day terlipressin treatment of bleeding esophageal varices to 10-day treatment period. Methodology: Of 25 patients with variceal bleeding, 15 were randomized to receive terlipressin for day 1-5 and placebo for day 6-10 (Group A), and 10 to receive terlipressin for day 1-10 (Group B). Results: The bleeding was stopped in 24 patients (96%). Rebleeding till day 42 was observed in 9 (36%) patients (5 in group A, 4 in group B, ns). 2 patients died in group B (due to rebleeding till day 5) and one in group A (rebleeding between day 510). Transfusion needs were lower in group B (2.7 +/- 2.6TU compared to 4.13 +/- 5.8 TU in group A, ns). Serious AE leading to treatment discontinuation were observed in 1 patient in group A (peripheral ischemia) and none in B, non-significant AE in 3 patients in group A (hypertension), and in 3 in group B (hypertension, hyponatremia, epiparoxysm). Conclusions: Prolonged treatment with terlipressin did not prove significant decrease of mortality or bleeding recurrence; lower rebleeding rate after day 5 and tendency towards lower transfusion requirements were observed. Prolonged treatment had no influence on AE rate. (en)
Title
  • Double-Blind Randomized Multicenter Study Comparing the efficacy and safety of 10-day to 5-day terlipressin treatment of bleeding esophageal varices
  • Double-Blind Randomized Multicenter Study Comparing the efficacy and safety of 10-day to 5-day terlipressin treatment of bleeding esophageal varices (en)
skos:prefLabel
  • Double-Blind Randomized Multicenter Study Comparing the efficacy and safety of 10-day to 5-day terlipressin treatment of bleeding esophageal varices
  • Double-Blind Randomized Multicenter Study Comparing the efficacy and safety of 10-day to 5-day terlipressin treatment of bleeding esophageal varices (en)
skos:notation
  • RIV/00023001:_____/09:00002713!RIV12-MZ0-00023001
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • I, P(NR9406), S, V
http://linked.open...iv/cisloPeriodika
  • 90
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 311316
http://linked.open...ai/riv/idVysledku
  • RIV/00023001:_____/09:00002713
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • Adverse events; Cirrhosis; Hyponatremia; Renal parameters; Terlipressin; Variceal bleeding (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • GR - Řecká republika
http://linked.open...ontrolniKodProRIV
  • [FC0275AB12A2]
http://linked.open...i/riv/nazevZdroje
  • Hepato-gastroenterology
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...vavai/riv/projekt
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 56
http://linked.open...iv/tvurceVysledku
  • Drastich, Pavel
  • Procházka, V.
  • Špičák, Julius
  • Dolina, J.
  • Mareček, Z.
  • Lata, J.
  • Bruha, R.
  • Ehrmann, J.
  • Taimr, Pavel
  • Kroupa, R.
  • Petrtyl, J.
  • Urbanek, P.
  • Vrzalova, D.
issn
  • 0172-6390
number of pages
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 67 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software